Table 2 Tumor characteristics of evaluable patients
Disease characteristic (n = 1894) | Total, n (%) | CT, n (%) | No CT, n (%) |
|---|---|---|---|
Tumor dimensions (pT) | |||
· pT1mic-pT1a-pT1b | 422 (22.3%) | 132 (31.3%) | 290 (68.7%) |
· pT1c | 846 (44.7%) | 515 (60.9%) | 331 (39.1%) |
· pT2-pT3-pT4b | 626 (33.0%) | 448 (71.6%) | 178 (28.4%) |
Axillary lymph node status (pN) | |||
· pN0 | 1155 (61.0%) | 502 (43.5%) | 653 (56.5%) |
· pN1 | 551 (29.1%) | 422 (76.6%) | 129 (23.4%) |
· pN2 | 119 (6.3%) | 106 (89.1%) | 13 (10.9%) |
· pN3 | 69 (3.6%) | 65 (94.2%) | 4 (5.8%) |
Estrogen and Progesterone Receptor (ER/PgR) | |||
· ER or PgR-positive (≥1%) | 1619 (85.5%) | 829 (51.2%) | 790 (48.8%) |
· ER and PgR 0% | 274 (14.5%) | 266 (97.1%) | 8 (2.9%) |
· Unknown | 1 (0.1%) | 0 (0.0%) | 1 (100%) |
Proliferative index (Ki67 or MIB-1) | |||
· Low (≤20%) | 1150 (60.7%) | 499 (43.4%) | 651 (56.6%) |
· High (>20%) | 691 (36.5%) | 562 (81.3%) | 129 (18.7%) |
· Unknown | 53 (2.8%) | 34 (64.2%) | 19 (35.8%) |
HER2 | |||
· Positive | 305 (16.1%) | 269 (88.2%) | 36 (11.8%) |
· Negative | 1463 (77.2%) | 761 (52.0%) | 702 (48.0%) |
· Unknown | 126 (6.7%) | 65 (51.6%) | 61 (48.4%) |
Biological type | |||
· Luminal A | 923 (48.7%) | 352 (38.1%) | 571 (61.9%) |
· Luminal B | 342 (18.1%) | 230 (67.3%) | 112 (32.7%) |
· HER2 | 305 (16.1%) | 269 (88.2%) | 36 (11.8%) |
· Triple negative | 165 (8.7%) | 161 (97.6%) | 4 (2.4%) |
· Unknown | 159 (8.4%) | 83 (52.2%) | 76 (47.8%) |